REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 14th, 2003 • Bradley Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made and entered into as of July 24, 2003, by and between Bradley Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and UBS Securities LLC and Raymond James & Associates, Inc. (collectively, the “Initial Purchasers”), for whom UBS Securities LLC is acting as representative, pursuant to that certain Purchase Agreement, dated as of July 18, 2003 (the “Purchase Agreement”) between the Company and the Initial Purchasers.
ContractFirst Supplemental Indenture • August 14th, 2003 • Bradley Pharmaceuticals Inc • Pharmaceutical preparations • New York
Exhibit 4.1.1 BRADLEY PHARMACEUTICALS, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY as Trustee _____________________________ FIRST SUPPLEMENTAL INDENTURE Dated as of July 24, 2003 _____________________________ 4% CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2013 FIRST SUPPLEMENTAL INDENTURE, dated as of July 24, 2003 (the “First Supplemental Indenture”), between BRADLEY PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and AMERICAN STOCK TRANSFER & TRUST COMPANY, as Trustee (herein called the “Trustee”). WHEREAS, the Company and the Trustee have entered into an Indenture dated as of June 11, 2003 (the “Indenture”) relating to the Company's 4% Convertible Senior Subordinated Notes due 2003 (the “Notes”); WHEREAS, the Company desires to increase the aggregate principal amount of Notes issuable pursuant to the Indenture by $4,000,000, such that an aggregate of $37,000,000 in aggregate principal amount of Notes are issuable pursuant to the Indenture; and WHEREAS,
